Carcinoma of the breast: detection with MR imaging versus xeromammography

Detectability of breast cancer with magnetic resonance (MR) imaging versus xeromammography was quantitatively compared. MR images were obtained of breasts of 120 women who underwent xeromammography. T1 values were determined for masses larger than 2 cm. Cancer was histologically confirmed in 39 breasts and was considered excluded from 81 due to results of biopsy, cyst aspiration, or sonography or absence of change in xeromammographic findings over time. Images were blindly interpreted by three observers, and results were expressed as receiver operating characteristic curves. Detectability of breast cancer was substantially better with xeromammography than with MR imaging for all observers (P less than .03, 10(-6), and .001). On MR images, spiculation of a mass, distorted architecture, skin thickening, and nipple or skin retraction were specific but relatively insensitive indicators of cancer. Masses with smooth, distinct margins and signal intensity greater than that of fat on T2-weighted images were always benign. Other findings and T1 values were not diagnostically useful. The authors conclude that xeromammography is superior to MR imaging in detection of breast cancer.     

Trasylol in acute pancreatitis

Conclusions Trasylol in the dosage used in this trial was of no value in the treatment of acute pancreatitis. There is some evidence, both experimental and clinical, to suggest that a further double-blind trial of Trasylol using very much larger doses would be valuable. In the meanwhile, and until we have further knowledge on the matter, it would appear that if Trasylol is given for acute pancreatitis at least 200,000 U. per day should be administered. Obviously with this dosage a close watch must be kept for toxic effects.The Trasylol used in this study was supplied by Farbenfabriken Bayer A. G., Leverkusen, West Germany. Mr. G. H. Darling, F.P.S., made up the doses used in the blind trial and controlled its key.